Locus of control flip: management says the outcome is in its own hands, and names what it controls
The model's full reasoning — Q2 2022 call → NOThe question asks whether management conveys that the company's results over the coming periods will be determined mainly by things the company itself controls, and whether management backs that stance by pointing to at least one specific, nameable driver it controls that is already real today. Let me analyze the transcript carefully. Key elements: 1. Management acknowledges disappointing results and blames external factors (plan parity, CMS marketing review, labor market) for the current quarter's underperformance. 2. Management discusses a strategic review and plans for the future. 3. Management mentions specific actions: hiring agents earlier, reducing flex agent headcount, resetting baseline, changes to LTV assumptions, scrutinizing corporate expense structure. 4. Management highlights SelectRx as a bright spot with 40,000 gross enrollments and 10,000 active paying members. Now, the question asks about the COMING PERIODS - will results be determined mainly by things the company controls? Looking at management's framing: - They discuss resetting the baseline, reducing operating leverage, hiring earlier, etc. - these are internal actions. - They highlight SelectRx growth as a bright spot - this is a controllable driver already in motion (40,000 enrollments, 10,000 active members, scaling). However, the overall tone is heavily focused on external headwinds (plan parity, CMS issues, labor market) as the cause of the problems. The forward-looking statements are more about "we will do X, Y, Z" rather than "our results are in our own hands." Let me look for the specific posture: - Tim says: "we view these results as unacceptable" and discusses strategic review. - The actions mentioned are mostly forward-looking plans (hiring earlier next year, reducing headcount, etc.) - these are plans, not yet in motion. - SelectRx is presented as already real and scaling - 40,000 enrollments, 10,000 active members, with confidence in reaching 25,000 by year-end. The question requires BOTH halves: 1. An ownership stance toward the future - management framing the path ahead as substantially self-determined. 2. A named, controllable driver already in motion.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| SFIX | Stitch Fix, Inc. | Q3 2024 | 2024-06-04 | C+ |
| RCEL | AVITA Medical, Inc. | Q1 2024 | 2024-05-14 | F |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| TNET | TriNet Group, Inc. | Q1 2024 | 2024-04-26 | C |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| GPRO | GoPro, Inc. | Q4 2023 | 2024-02-07 | F |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| PTLO | Portillo's Inc. | Q2 2023 | 2023-08-05 | B |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TSSI | TSS, Inc. | Q4 2022 | 2023-04-03 | D |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| HROW | Harrow Health, Inc. | Q4 2021 | 2022-03-10 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| CLVT | Clarivate Plc | Q2 2021 | 2021-07-31 | B+ |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| ASND | Ascendis Pharma A/S | Q1 2018 | 2018-05-30 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| SCVL | Shoe Carnival, Inc. | Q4 2017 | 2018-03-27 | C+ |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| ITCI | Intra-Cellular Therapies, Inc. | Q4 2017 | 2018-03-01 | D |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| STKL | SunOpta Inc. | Q2 2017 | 2017-08-09 | C+ |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| MRIN | Marin Software Incorporated | Q4 2016 | 2017-02-28 | D |
| SXT | Sensient Technologies Corporation | Q4 2016 | 2017-02-10 | A |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| EFSC | Enterprise Financial Services Corp | Q4 2016 | 2017-01-24 | B+ |
| RPM | RPM International Inc. | Q2 2017 | 2017-01-05 | D |
| LEE | Lee Enterprises, Incorporated | Q4 2016 | 2016-12-09 | C |
| FATE | Fate Therapeutics, Inc. | Q3 2016 | 2016-11-07 | C |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
| GIS | General Mills, Inc. | Q4 2016 | 2016-06-29 | B+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
TNET · Q1 2024 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing future results as largely self-determined through internal levers like offsetting attrition with new sales (which they expect to "consistently achieve"), disciplined execution in sales/retention/expenses, and a strategy review to align resources for profitable growth. They back this with specific, already-real drivers: 50 % YoY ACV new sales growth, 28 % YoY growth in tenured sales reps plus productivity gains, and nearly positive sequential core WSE growth in Q1. While acknowledging external headwinds (economic hiring softness, insurance cost inflation), they repeatedly redirect to what they control and point to these internal actions as the primary drivers of improvement. The stance is coherent and not generic. Answer: YES. The question requires "mainly" and "rather than by market conditions, etc."; the transcript meets that threshold by repeatedly emphasizing internal control and execution while treating external factors as secondary headwinds they are managing.
GPRO · Q4 2023 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing 2024 results as driven primarily by its own actions: the retail expansion already underway (3,200 doors added, 7,000 targeted), new product launches (four SKUs in 2024), the Forcite acquisition closed this quarter, and the Quik desktop app launched 24 hours ago. They repeatedly tie future growth to these internal levers rather than external demand or macro conditions, while noting external factors only as temporary Q4 headwinds. This meets both criteria. NO if it were mainly external or generic. YES. The stance is coherent and backed by a named, already-real driver (ret 3200 doors + strategy shift). The answer is YES. The question is answered with YES. The final answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES. The answer is YES.
HROW · Q4 2021 → YESThe question is: Does management convey that the company's results over the coming periods will be determined mainly by THINGS THE COMPANY ITSELF CONTROLS, rather than by market conditions, etc., AND ...YES The transcript shows management framing the path ahead as substantially self-determined through its own execution and actions (e.g., "positioning Harrow Health to fulfill its vision," "executing on that vision," "we are expanding our existing commercial infrastructure," "establishing our own internal analytical lab," "we expect to see 2023 number looks like 2024, 2025" via "profits that this team has been able to generate," and "we have that amazing commercial team and we have a large customer base" for launches without dilution). They redirect from external factors like COVID to internal progress and state they will "not dilute our shareholders necessarily to launch AMP-100" due to internal capabilities.